EUVIMEDEUVIMED entdecken
Open Access

Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials

Yongqi Liu, R James White iD, Sang Wan Lee, Charles Fauvel iD, Priscilla Correa-Jaque, Shili Lin iD, Raymond L Benza iD

American Journal of Respiratory and Critical Care Medicine · 2026

DOI: 10.1093/ajrccm/aamaf003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, 2026. Verfasst von Yongqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, The Ohio State University, Columbus, OH, United States. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Pulmonary arterial hypertension (PAH) clinical trials largely rely on clinically relevant intermediate outcomes, as mortality and lung transplant are infrequent and remote outcomes. The change in 6-minute walk distance (Δ6MWD) is utilized as an intermediate endpoint and is used as a surrogate for clinical worsening events.

Objectives

We investigate whether the change in 4 composite risk assessment scores—REVEAL Lite 2 (ΔRL2), European Four Strata (ΔE4), European Three Strata (ΔE3), and French Noninvasive score (ΔFPHN)—are potentially stronger surrogate endpoints than the single-component Δ6MWD in PAH studies.

Methods

Using data from the AMBITION and FREEDOM-EV trials, we estimated the percentage of treatment effect in reducing clinical worsening events within 1 year that is attributed to the change on each of the 5 scores between baseline and 12–16 weeks’ follow-up. We conducted bootstrap analysis to provide head-to-head comparisons. Measurements and Main Results Our analysis shows that all 4 composite scores mediate significantly more of the treatment effect compared to 6MWD (29% for ΔRL2 and ΔE4 compared to 19% for Δ6MWD; both P <10−15). The drug treatment effect accounted for by all 5 scores increases with intermediate/high-risk patients, and ΔRL2 had the highest % mediation (37% for ΔRL2 vs 28% for Δ6MWD; P < 10−15).

Conclusions

RL2 and E4 were the strongest mediators, with RL2 showing the highest mediation in intermediate/high-risk patients. Until better surrogates are found that mediate over 50% of the treatment effect, RL2 or E4 may serve as alternatives to the 6MWD as intermediate endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryPulmonary Arterial HypertensionHumansRisk AssessmentWalk TestBiomarkersFemaleMaleMiddle AgedAntihypertensive AgentsDisease Progression

Stichwörter der Autor:innen

6MWDRL2mediation analysispulmonary arterial hypertensionsurrogate endpoint

Substanzen

BiomarkersAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Statistics, The Ohio State University, Columbus, OH, United States.
  • Division of Pulmonary and Critical Care Medicine, University of Rochester, NY, United States.
  • Department of Cardiology, Rouen University Hospital, INSERM U1096, Rouen, France.
  • Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York City, NY, United States.

ORCID-Profile: R James White, Charles Fauvel, Shili Lin, Raymond L Benza

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Liu, Y., White, R. J., Lee, S. W., Fauvel, C., Correa-Jaque, P., Lin, S., & Benza, R. L. (2026). Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamaf003

Vancouver

Liu Y, White RJ, Lee SW, Fauvel C, Correa-Jaque P, Lin S, et al. Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials. American Journal of Respiratory and Critical Care Medicine. 2026. doi:10.1093/ajrccm/aamaf003

BibTeX
@article{Liu2026,
  author = {Liu, Yongqi and White, R James and Lee, Sang Wan and Fauvel, Charles and Correa-Jaque, Priscilla and Lin, Shili and Benza, Raymond L},
  title = {Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2026},
  doi = {10.1093/ajrccm/aamaf003}
}
Kostenlos starten →